Sure, I can try.
The questions around the common drug review are probably best answered by the common drug review, but from the perspective of the partner departments, it is really complicated, there's no question. But when you think about the amount of money we're spending on pharmaceuticals, you want to make sure that the drugs we're providing are, first of all, safe. You want to make sure that a really expensive drug is really going to be worth the extra investment of taxpayers' dollars and that it's not just a more expensive drug that does the same thing, or something not as good even as a drug that's already on the formulary.
So there are different groups that look at the drugs from different perspectives. Then among the six partner departments, we do try to learn from each other, to understand what one department is doing, how that applies to the other. So while it's extremely complicated, each committee has its own particular value that it adds.
The drug utilization evaluation is really important from the point of view of taking a look at people who are really high consumers of pharmaceuticals and trying to take a look at whether there are unintended consequences of so many drugs being consumed by one individual, and again making sure that we have experts who are looking at our data to highlight whether or not we have people who are having problems from drug interactions.